BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/10/2014 6:20:00 PM | Browse: 1293 | Download: 1013
 |
Received |
|
2013-09-11 08:29 |
 |
Peer-Review Started |
|
2013-09-11 14:47 |
 |
To Make the First Decision |
|
2013-10-14 14:07 |
 |
Return for Revision |
|
2013-10-14 18:08 |
 |
Revised |
|
|
 |
Second Decision |
|
2013-11-04 16:22 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2013-11-05 08:32 |
 |
Articles in Press |
|
|
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
2013-11-11 01:31 |
 |
Typeset the Manuscript |
|
2013-11-21 14:28 |
 |
Publish the Manuscript Online |
|
2013-11-26 22:03 |
Category |
Gastroenterology & Hepatology |
Manuscript Type |
Minireviews |
Article Title |
Hepatitis B virus reactivation with rituximab-containing regimen
|
Manuscript Source |
Invited Manuscript |
All Author List |
Yutaka Tsutsumi, Yoshiya Yamamoto, Joji Shimono, Hiroyuki Ohhigashi and Takanori Teshima |
Funding Agency and Grant Number |
|
Corresponding Author |
Yutaka Tsutsumi, MD, PhD, Department of Hematology, Hakodate Municipal Hospital, Hakodate 1-10-1, Minato-cho, Hakodate 041-8680, Japan. yutsutsu@shore.ocn.ne.jp
|
Key Words |
Rituximab; Hepatitis B virus; Reactivation; Chemotherapy; Lamivudine; Non-Hodgkin's lymphoma |
Core Tip |
The deleterious effects of hepatitis B virus (HBV) reactivation in rituximab-containing chemotherapy regimens have been reported and the effect of lamivudine treatment in the prevention of HBV reactivation is also well documented. Once reactivated, HBV may lead to death due to hepatitis. In this review, we discuss the factors of preventive lamivudine treatment (especially in the course of HBV antibody), including to whom and for how long the drug should be given, based on case studies and reports that span rituximab’s debut in 2002 on the Japanese market to June 2013.
|
Publish Date |
2013-11-26 22:03 |
Citation |
Tsutsumi Y, Yamamoto Y, Shimono J, Ohhigashi H, Teshima T. Hepatitis B virus reactivation with rituximab-containing regimen. World J Hepatol 2013; 5(11): 612-620 |
URL |
http://www.wjgnet.com/1948-5182/full/v5/i11/612.htm |
DOI |
http://dx.doi.org/10.4254/wjh.v5.i11.612 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345